The association of anti-CCP antibodies with disease activity in rheumatoid arthritis by Serdaroğlu, Münevver et al.
Rheumatol Int (2008) 28:965–970
DOI 10.1007/s00296-008-0570-3
123
ORIGINAL ARTICLE
The association of anti-CCP antibodies with disease activity 
in rheumatoid arthritis
Münevver Serdaroflu · Haoim ÇakÂrbay · 
Orhan Defer · Sevil Cengiz · Sibel Kul 
Received: 17 July 2007 / Accepted: 16 March 2008 / Published online: 17 April 2008
© The Author(s) 2008
Abstract Antibodies to citrullinated proteins have been
described in patients with rheumatoid arthritis (RA) and
these appear to be the most speciWc markers of the disease.
Our objective was to determine the frequency of antibodies
to cyclic citrullinated peptides (CCPs) in patients with RA
and the association of anti-CCP antibodies with disease
activity, radiological erosions and HLA DR genotype.
Forty patients with RA and 38 patients with Wbromyalgia
were included in this study. Serum samples were collected
from both patient groups with RA and Wbromyalgia. Anti-
CCP was measured by the corresponding enzyme-linked
immunosorbent assay. Additionally, erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), rheumatoid
factor (RF), disease activity score (DAS), visual analog
scala (VAS), HLA genotype and radiographic information
were determined in patients with RA. The rate of sensitivity
and speciWcity of anti-CCP reactivity for the diagnosis RA
were measured (sensitivity 50%, speciWcity100%). There is
no signiWcant diVerence between anti-CCP (+) and anti-
CCP (¡) RA patients for DAS28, VAS, ESR, CRP, disease
duration, HLA genotype, and radiological assessment of
hand. However, there was a signiWcant diVerence between
anti-CCP (+) and anti-CCP (¡) RA patients for RF and the
radiological assessment of left and right wrists (respectively,
P <0 . 0 5 ,   P =0 . 0 4 ,   P = 0.01). There was no signiWcant cor-
relation between anti-CCP antibody and ESR, CRP, VAS,
DAS 28 or radiological assessment. A small but signiWcant
correlation was found between RF and anti-CCP antibody
(P =0 . 0 2 ,   r =0 . 3 5 ) .
Keywords Rheumatoid arthritis · Anti-CCP antibodies · 
Rheumatoid factor · Disease activity · Radiological 
erosions
Introduction
Rheumatoid arthritis (RA) is a systemic inXammatory dis-
ease characterized by chronic and erosive poliarthritis
caused by abnormal growth of sinovial tissue or pannus,
and causes irreversible joint disability. It is the most com-
mon inXammatory arthritis, aVecting from 0.5 to 1% of the
general population worldwide, with a female/male ratio of
2.5:1. The disease may appear at any age, but it is most
common among those aged from 40 to 70 years and its inci-
dence increases with age [1]. Apart from pain, RA is asso-
ciated with reduction of functional capacity, and increased
comorbidity and mortality [2, 3].
For decades, the diagnosis of RA has been primarily
based on clinical manifestations. However, especially dur-
ing the Wrst few months of the disease, the 1987 revised cri-
teria of the American College of Rheumatology (ACR) are
rarely met [4]. About one-third of the patients with persis-
tent arthritis do not fulWll the classiWcation criteria, so it is
often diYcult to diagnose RA in the very early stages of the
disease [5]. On the other hand, numerous studies have
shown that substantial irreversible joint damage occurs
within the Wrst 2 years [6, 7]. In many cases, irreversible
damage of the joint cartilage has already occurred by the
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time laboratory and radiological parameters have conWrmed
the clinical daignosis RA [8].
Because of the highly variable and unpredictable course
of the disease, current therapeutic strategies in RA are
increasingly aggressive regimens early in the course of the
disease. Therefore, diagnostic tests with high-speciWcity are
desirable for deciding on the optimal treatment [9].
So far, serological support in the diagnosis of RA was
mainly based on the presence of rheumatoid factors (RF)
[10]. RF can be detected in up to 70–80% of RA patients
[11]. The ACR criteria for RA diagnosis include the pres-
ence of RF, a decision that has contributed to the widely
routine use of this test as a diagnostic marker for RA in
most clinical laboratories. However, these antibodies are
not very speciWc for RA and can also be detected in other
rheumatic diseases, infectious diseases, and even in 3–5%
of apparently healthy individuals [10, 12].
In recent years, many studies on antibodies against
cyclic citrullinated peptide (CCP) have demonstrated that
these antibodies are highly speciWc and predictive for RA
[13] that they can be detected years before onset [14], and
also that they are associated with joint destruction [15].
Furthermore, the presence or absence of these antibodies
seems to be a stable trait [16]. Anti-CCP antibodies are
detected in SE-positive as well as in SE-negative RA
patients. Carriership of SE alleles in RA is associated with
the presence of anti-CCP antibodies [17].
This article investigates the sensitivity and speciWcity of
the anti-CCP antibody in RA and association of it antibody
with disease activity and radiological Wndings.
Materials and methods
This study was conducted in the outpatient rheumatology
unit of the Karadeniz Technical University Medical Fac-
ulty, Türkiye. Forty women patients with RA (median age,
48.3 years, range 22–74) who met at least four 1987 Amer-
ican College of Rheumatology (ACR) criteria and 38
women patients with Wbromyalgia (median age 44,
range31–60), who were considered as control group, were
included in this study. Serum samples were obtained from
both patient groups with Wbromyalgia and RA and were ali-
quoted and stored at ¡80°C until assayed. Additionally,
erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), rheumatoid factor (RF), disease activity score 28
(DAS), visual analog scala (VAS), and human leukocyte
antigen (HLA) genotype were recorded in patients with
rheumatoid arthritis. Hand radiographs were taken at the
beginning of study and radiological assessment was
performed by Larsen score.
Serum antibodies directed to the cyclic citrullinated
peptide (anti-CCP) were assessed with a commercial
enzyme-linked immunosorbent assay (ELISA), (Aida
gmbh, Germany, RA/CP detect, Ref 10165) and it was con-
sidered as positive if the antibody titer was greater than
15 U/ml.
These results were analyzed by SPSS (version 11.5).
Student’s t test for continuous variables was used to exam-
ine the signiWcance of diVerences between the diVerent
groups. Non-parametric Mann–Whitney test was used to
compare non-paired sets. P-value less than 0.05 was
regarded as signiWcant. Correlation between variables was
assessed by Spearman’s correlation coeYcient and Pearson
correlation.
Results
The anti-CCP test demonstrated a speciWcity of 100% and
sensitivity of 50% for RA when compared with controls.
The sociodemographic and disease-related characteristics
of the patient with rheumatoid arthritis were summarized in
Table 1. The mean § SD age of the patients was 48.3 §
12.8 years, and all of them were females. The most
common treatments received included combination of
methotrexate (MTX), sulfosalazine (SSZ) and deltacortril
Table 1 Sociodemographic and disease related characteristics of 40
patients with rheumatoid arthritis
* Except where indicated otherwise, values are the number (%)
Characteristics
Age, mean § SD years 48.3 § 12.8
BMI, mean § SD 26.9 § 4.4
Female 40 (100)
RF, mean § SD 103.5 § 154
Anti-CCP, mean § SD (U/ml) 104.6 § 132.2
DAS28, mean § SD 3.9 § 1.3
Remission 5 (12.5)
Low activity 5 (12.5)
Median activity 20 (50)
High activity 10 (25)
Disease duration § years 6.8 § 6.6
ESR, mean § SD (mm/1st h) 29.2 § 22.9
RF 26/40  (65) 
HLADR3 4/36 (11.1)
HLADR4 10/36 (27.8)
VAS, mean § SD 4.8 § 1.7
CRP, mean § SD (mg/l) 1.9 § 3.0
Drug treatment
MTX/DTC 11 (27.5)
SSZ/DTC 7 (17.5)
MTX/SS/DTC 13 (32.5)
MTX/HQC/DTC 2 (5)
NSAID 7  (17.5)Rheumatol Int (2008) 28:965–970 967
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(DTC) (32.5%), followed by the combination of methotrex-
ate and deltacortril (27.5%), sulfasalazine and deltacortril
(17.5%), nonsteroidal anti-inXammatory drugs (17.5%) and
MTX-hydroxychloroquine (HCQ) (5%). On average, dis-
ease duration (S.D.) was 6.8 § (6.6) years. RF was positive
in 26 (65%) patients and negative in 14 (35%) patients. The
anti-CCP was positive in 20 (50%) patients and negative in
20 (50%) patients. The mean § SD titer of the anti-CCP
was 104.6 § 132.2 U/ml. The distribution of anti-CCP
titers was demonstrated in Fig. 1. HLA genotypes of the
four patients could not be studied. Five (12.5%) patients
were in remission. In Wve (12.5 %) patients, DAS 28 was
low, in 20 patients it was median, and in ten patients
severely active.
In 18/20 patients (90%) with anti-ccp positive and in 8/
20 patients (40%) with anti-CCP negative, RF was positive
and there were signiWcant diVerences between anti-CCP
positive and negative patients for rheumatoid factor
(P <0 . 0 5 )  ( T a b l e2). The analysis of serological parameters
of disease activity (ESR, CRP, DAS 28 and VAS) and
disease duration between the anti-CCP positive and nega-
tive patients with rheumatoid arthritis showed no signiW-
cant diVerence in any parameter (P > 0.05). According to
radiological assessment of hand radiography by Larsen
score (0–100), there was no signiWcant diVerence between
the anti-CCP positive and negative patients with RA.
However, the analysis of wrist radiography (0–5) between
the anti-CCP positive and negative patients with RA
showed signiWcant diVerence with a higher score in anti-
CCP positive patients (P <0 . 0 5 )  ( T a b l e3). There was also
no signiWcant correlation between anti-CCP antibody and
ESR, CRP, VAS, DAS 28 or radiological assessment. A
small but signiWcant correlation was found between RF and
anti-CCP antibody (r =0 . 3 ,  P = 0.02) (Table 4; Fig. 2).
Additionally, there was a signiWcant correlation between
DAS 28 and RF, ESR, CRP, VAS, radiological assessment
of right wrist or left wrist (r = 0.3,  P =0 . 0 3 ;  r =0 . 6 ,
P <0 . 0 0 5 ;  r = 0.4,  P <0 . 0 0 5 ;  r =0 . 7 ,  P <0 . 0 0 5 ;  r =0 . 3 ,
P =0 . 0 3 ;   r = 0.4, P = 0.02, respectively) (Table 5).
Discussion
The modern trend of RA treatment has been changed to
start treatment as early as possible, based on the concept
that early control of inXammation results in reduced joint
damage [18]. It therefore is important to diVerentiate
between RA and other forms of arthritis early after the
onset of symptoms [19, 20]. Although the 1987 American
College of Rheumatology classiWcation criteria for RA [4]
are often used in clinical practice as diagnostic tool for RA,
they are not very well suited for the diagnosis of early RA
Fig. 1 The disturbance of the titers of anti-CCP antibodies in control
group and patients with RA
Table 2 DiVerence in the serological parameter in the CCP-negative
versus CCP-positive patients with RA
Anti-CCP positive 
patients (n =2 0 )
Anti-CCP negative 
patients (n = 20)
P-value
Age 47.2 § 14.5 49.5 § 11 0.593
ESR 25.9 § 19.4 32.5 § 26 0.373
CRP 1.5 § 2.4 2.2 § 3.7 0.440
Disease duration 7.4 § 7.5 6.2 § 5.7 0.614 
VAS 5.1 § 1.7 4.5 § 1.6 0.313
DAS28 4.1 § 1.3 3.8 § 1.4 0.459
RF (+) 18/20 (90) 8/20 (40) 0.001
HLADR3 (+) 1 /19 (5.3) 3/19 (17.6) 0.258
HLADR4 (+) 4 /15 (21.1) 6/17 (35.3) 0.341
Table 3 DiVerence in the radiologic assessment of hand and wrist by
Larsen score in CCP-negative versus CCP-positive patients with RA
Anti-CCP positive 
patients (n = 20)
Anti-CCP negative 
patients (n =2 0 )
P-value
Rigt hand score, 
mean § SD
12.7 § 8.4 8.2 § 5.6 0.051
Right wrist score, 
mean § SD
2.4 § 1.5 1.4 § 1.3 0.010
Left hand score, 
mean § SD
11.2 § 7.8 10.0 § 7.6 0.362
Left wrist score, 
mean § SD 
2.3 § 2.3 1.4 § 1.3 0.044968 Rheumatol Int (2008) 28:965–970
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[21–23]. The ACR criteria rely heavily on the expression of
clinical symptoms of RA, but in early RA these clinical
parameters are often not (yet) manifest. Therefore, a spe-
ciWc and sensitive (serological) marker, which is present
very early in the disease, is needed. Rheumatologists need
to be able to target the use of potentially toxic and expen-
sive drugs to those patients, where the beneWts clearly out-
weigh the risks [23, 24]. Therefore a good marker should
ideally be able to predict the erosive or nonerosive progres-
sion of the disease.
In patients with RA, we found a sensitivity of 50% and
speciWcity of 100% for anti-CCP. Schellekens et al. [25]
reported that ELISA methods using the cyclic citrullinated
peptide (CCP-ELISA), in a series of 149 RA and 312
control sera, had a diagnostic sensitivity of 48% for a spec-
iWcity of 96%. Kroot et al. [26] identiWed 66% positive RA
serum samples with CCP-ELISA. Lee and Schur [27]
found a sensitivity of 66% and speciWcity of 90.4%. Dubuc-
quoi et al. [28] describe a sensitivity of 85% and a speciWc-
ity of 90.9% for anti-CCP. Although the speciWcity of
anti-CCP antibodies in RA is more than 90% in almost all
reports, the prevalence (sensitivity) of the same antibodies
ranges from 33 to 87.2%. Such a discrepancy in sensitivity
might reXect diVerent cutoV levels, racial and genetic back-
grounds, as well as the diVerences of used antigens and
detection techniques among reports [29]. Another impor-
tant point concerning the diagnostic value of CCP is that
about 35–40% of the RF-negative RA patients score posi-
tively for anti-CCP. In our study, only 2/14 (14.3%)
patients with RF-negative RA were positive for anti-CCP
antibodies and 12/14 (85.7%) patients with RA were nega-
tive.
The value of anti-CCP antibodies and RF for predicting
the outcome of RA, clinical signs of disease activity, and
the severity of radiographic joint damage has been investi-
gated recently. The studies by van Jaarsveld et al. [30],
Kroot et al. [26] and Meyer et al. [15], all support the thesis
that RA patients, positive for CCP, develop signiWcanly
more radiological damage than CCP-negative patients.
Lately, Visser et al. [31] assessed a clinical prediction
model in early RA patients for the three forms of arthritis
outcome: self-limiting, persistent nonerosive and persistent
erosive arthritis in which CCP was strongly associated with
erosive arthritis, more than RF. Forslind et al. [32] reported
the role of Anti-CCP in the radiological outcome in 379
cases with early RA, and concluded that anti-CCP as well
as the baseline Larsen score and ESR was an independent
predictor of radiological damage and progression in multi-
ple regression analysis. In our study, CCP positive patients
Table 4 The correlation between anti-CCP and other parameters of
disease activity
X § SD Anti-CCP
ESR 29.2 § 22.9 P =0 . 5 4
r = ¡0.11
CRP 1.9 § 3.0 P =0 . 4 6
r = ¡0.1
VAS 4.8 §  1.7  P =0 . 0 9
r = ¡0.02
DAS 28 3.9 § 1.3 P =0 . 6 3
r =0 . 0 7
Left hand  8.9 § 7.6  P =0 . 7 5
r =0 . 0 5
Right hand 8.1 §  5.6  P =0 . 3 7
r =0 . 1 4
Left wrist  1.3 § 1.2 P =0 . 4 9
r =0 . 1 1
Right wrist 1.3 § 1.2 P =0 . 1 0
r =0 . 2 6
RF 103.4 § 154.1 P =0 . 0 2
r =0 . 3 5
Fig. 2 The correlation between anti-CCP antibodies and RF
Table 5 The correlation of DAS-28 with other parameters of disease
activity
X § SD DAS 28
RF 103.4 § 154.1 P =0 . 0 3
r =0 . 3
ESR 29.2 § 22.9 P <0 . 0 0 5
r =0 . 6
CRP 1.9 § 3.0 P <0 . 0 0 5
r =0 . 4
VAS 4.8 § 1.7 P <0 . 0 0 5
r =0 . 7
Right wrist 1.3 § 1.2 P =0 . 0 3
r =0 . 3
Left wrist 1.3 § 1.2 P =0 . 0 2
r =0 . 4Rheumatol Int (2008) 28:965–970 969
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had a higher radiological score than CCP negative patients
for radiological assessment of wrist by Larsen method.
However, there was no signiWcant diVerence for radiologi-
cal assessment of hand by Larsen score.
In addition to the predictive value of CCP concerning
radiological damage, Kastbom et al. [16] showed that
CCP is good predictor of disease activity. CCP was even
better than RF in predicting disease activity over 3 years
after the diagnosis of recent onset of RA. Bas et al.
showed an association of IgA RF and anti-CCP with clini-
cal signs of disease activity [33, 34]. The high prevalance
of anti-CCP in RA patients with extensive disease activity
and severe radiological changes, and even more impres-
sively in RA patients who are IgM-RF-negative, suggests
that anti-CCP is more useful than the RF alone in the early
prediction of disease outcome and disease activity. We
found a signiWcant correlation between DAS 28 and RF,
ESR, CRP, VAS, radiological assessment of right wrist or
left wrist.
There is extensive evidence for the association between
certain frequently occurring HLA-DRB1 alleles, the so-
called “shared epitope” (SE)-encoding alleles (DRB1*0101,
*0102, *0104, *0401, *0404, *0405, *0408, *0413, *0416,
and *1001), and susceptibility to RA [35]. Recently, it has
been reported that the combination of anti-CCP antibodies
and HLA-DRB1 locus antigens is strongly associated with
more severe disease progressions [17,  36]. Most recent
analyses [37] suggested that the primary association of SE
alleles is with the development of erosions, especially in
RF-negative individuals [38, 39].
In our study, we could not Wnd correlation between anti-
CCP antibody and the serological markers of disease activ-
ity (ESR, DAS 28, CRP). There was a small, but signiWcant
positive correlation with anti-CCP and RF. Furthermore,
we could Wnd no signiWcant diVerence between anti-CCP
negative and anti-CCP-positive patients comparing ESR,
CRP, HLA genotype, DAS. However, there was a signiW-
cant diVerences between anti-CCP (+) and anti-CCP (¡)
RA patients for RF.
In conclusion, early development of erosive disease in
RA is associated with the presence of several autoantibod-
ies and the IgM RF is stil mostly used as a screening marker
in the diagnosis of RA. However, the anti-CCP antibody
assays have a comparable sensitivity in the diagnosis of RA
but a much higher speciWty. Further research, however, will
be necesssary to elucidate the exact mechanism and the sig-
niWcance of protein citrullination in etiopathogenesis of
RA.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
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